Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenecteplase for COVID-19 Respiratory Failure
NCT04505592Phase 2Completed
- Start
- Sep 2020
- Primary completion
- Mar 2022
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of tenecteplase in coronavirus disease 2019 (COVID-19), respiratory failure, acute respiratory distress syndrome (ARDS). Started Sep 2020; status: completed.
02
Drugs
tenecteplase
03
Conditions
coronavirus disease 2019 (COVID-19)respiratory failureacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04505592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04505592.